pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,002 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1845Endpoints1427Fierce Biotech747BioSpace737BioPharma Dive542raps245onclive165fda recalls
therapy area
allOncology12746Rare Disease3299Immunology2967Cardiology2834Hematology2267Pulmonology2221Vaccines
  • Sellas' galinpepimut-S cuts death risk by 41% in Phase 3 AML trial
    Sellas Life Sciences announced that its experimental immunotherapy galinpepimut-S achieved a 41% reduction in risk of death for patients with advanced acute myeloid leukemia in a Phase 3 trial. Th…
    STAT · 2h agoPositive readoutPositive↗ source
  • Capsida proposes new monkey testing framework after fatal gene therapy trial for brain disease
    Researchers presented investigations into a patient death that occurred in a gene therapy trial for a brain disease, which had raised concerns in the field. While the exact cause of death was not…
    STAT · 4h agoNegative readoutNegative↗ source
← prev
page 1 of 41
next →
116
fda medwatch113
globenewswire health73
fda press59
1822
Psychiatry & CNS1227
Ophthalmology1125
Endocrinology & Metabolism794
Pain785
Nephrology768
  • Marrow Therapeutics raises $173 million to develop infusion therapy for sickle cell disease
    Marrow Therapeutics was announced on Tuesday by biotech entrepreneur Romesh Subramanian. The new company aims to create an infusion therapy for sickle cell disease that matches the efficacy of gene…
    STAT · 2h agoDealPositive↗ source
  • Flavored nicotine tablets launch, raising concerns over appeal to youth
    New flavored nicotine tablets that melt in the mouth have been introduced by tobacco companies in several markets. Products include Zyn Melts by Philip Morris International in the United Kingdom…
    STAT · 4h agoNegative↗ source
  • FDA approves Roche's Wilserdly for advanced HR-positive, HER2-negative breast cancer with ESR1 mutation
    The U.S. Food and Drug Administration has granted approval to Roche's new oral breast cancer therapy, Wilserdly (giredestrant). The decision clears the way for the drug's launch in the United State…
    STAT · 17h agoApprovalPositive↗ source
  • CG Oncology’s cretostimogene cuts bladder cancer recurrence risk by 68% in Phase 3 trial
    CG Oncology reported that its experimental therapy, cretostimogene, achieved a 68% relative reduction in bladder cancer recurrence in a Phase 3 study of patients who had surgery for non‑muscle inva…
    BioPharma Dive · 21h agoPositive readoutPositive↗ source
  • FDA rejects Summit Therapeutics' ivonescimab combo, citing lack of survival benefit in lung cancer
    Summit Therapeutics and partner Akeso received a rejection from the U.S. Food and Drug Administration for their PD-1/VEGF antibody ivonescimab combined with chemotherapy. The agency said the data d…
    BioPharma Dive · 21h agoRegulatoryNegative↗ source
  • CG Oncology's bladder cancer immunotherapy cuts tumor recurrence risk by 68% in study
    CG Oncology reported that its bladder cancer immunotherapy, cretostimogene, achieved a 68% reduction in tumor recurrence compared with standard care. The treatment uses an engineered common cold v…
    STAT · 1d agoPositive readoutPositive↗ source
  • FDA rejects ivonescimab for lung cancer; J&J to acquire Ollin Biosciences for up to $3.3B, Senate votes on FDA commissioner
    The FDA has denied the application for ivonescimab as a treatment for lung cancer, halting its development for that indication. Johnson & Johnson announced a deal to purchase Ollin Biosciences, a…
    raps · 1d agoRegulatoryNeutral↗ source
  • Biotech sector rebounds but gains are uneven, with Chinese firms and a large Sofinnova fund leading the surge
    Biotech companies are experiencing a strong year overall, yet investor reactions to positive clinical data remain mixed. Chinese biotech firms are emerging as the top performers, outpacing many pe…
    STAT · 21h agoDealNeutral↗ source
  • Versant and Eli Lilly commit $100 million to launch Seawolf Therapeutics, a non-viral gene-therapy startup
    Versant Ventures, Eli Lilly and other investors announced a $100 million financing round to create Seawolf Therapeutics, a new company focused on non-viral gene delivery. The startup aims to overc…
    STAT · 1d agoDealPositive↗ source
  • Democrats adopt "Medicare for More" as new health-care expansion message
    Democrats in the House have agreed on a new policy slogan, "Medicare for More," signaling a push to broaden health‑care coverage. The phrase is meant to set the agenda apart from the more ambitiou…
    STAT · 1d agoNeutral↗ source
  • BeOne Medicines and Hengrui Lead STAT-WireScreen’s China Biotech Powerhouse 25 Ranking
    STAT and risk‑intelligence platform WireScreen have published a new ranking called China’s Biotech Powerhouse 25, which lists the most valuable publicly traded biotech companies in the country. Th…
    STAT · 1d agoNeutral↗ source
  • STAT+: Helus’ psychedelic drug improved depression in study but faces safety questions
    A psychedelic drug from Helus Pharma improved depression in a study, but is facing safety questions with a number of serious adverse events reported.
    STAT · 1d agoRegulatoryNeutral↗ source
  • Apple and OpenEvidence Begin Study of Experimental AI Health Chat App
    Apple and OpenEvidence have launched a study centered on an experimental AI-powered health chat application. The pilot allows users to link personal health data to the chatbot, which then provides…
    STAT · 1d agoNeutral↗ source
  • FDA proposes new classification that formally recognizes NAC as a dietary ingredient, ending its legal gray area
    The FDA announced a proposed rule that would create a new regulatory category for N-acetyl-L-cysteine (NAC), a product long sold as a dietary supplement. Under the proposal, NAC would be classifie…
    STAT · 19h agoRegulatoryPositive↗ source
  • STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
    The FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso.
    STAT · 1d ago↗ source
  • Novo files US and EU approval for etavopivat, its $1B acquired sickle-cell therapy
    Novo submitted regulatory applications in the United States and Europe for etavopivat, a sickle cell disease therapy it bought from Forma Therapeutics in a $1 billion transaction. The company says…
    BioPharma Dive · 3d agoApprovalPositive↗ source
  • Setbacks in two heart disease trials raise questions about future cardiovascular drug research
    A recent episode of The Readout LOUD highlighted the disappointing results of two high-profile heart disease drugs, noting that both failed to demonstrate benefit in recent studies. The failures w…
    STAT · 4d agoNegative readoutNegative↗ source
  • Synchron pauses second-generation brain-computer interface trial, says pause not safety related
    Synchron, a brain-implant startup, announced it is pausing enrollment in its second-generation brain-computer interface trial. Company officials emphasized the decision is operational and not driv…
    STAT · 3d agoNeutral↗ source
  • Scientists release detailed basal ganglia cell map, uncover new neuron linked to schizophrenia
    Scientists from a large international collaboration have created the most detailed map of the basal ganglia, a brain region that coordinates movement and emotion. The effort profiled over 25 millio…
    STAT · 4d agoPositive↗ source
  • American Cancer Society recommends routine PSA screening for men 50-69, strengthens guidance for high-risk groups
    The American Cancer Society (ACS) has updated its prostate-cancer screening guidelines, now advising men at average risk aged 50 to 69 to have a PSA blood test every two years. This replaces the 20…
    STAT · 5d agoRegulatoryPositive↗ source
  • Alnylam faces slowdown in Amvuttra sales, putting its growth ambitions at risk
    Alnylam’s market narrative has long hinged on the performance of its cardiomyopathy drug Amvuttra. The company once hoped the therapy could lift its valuation toward the $100 billion range. Recent…
    STAT · 5d agoNegative↗ source
  • Biogen prepares to unveil results of litifilimab Phase 3 TOPAZ-1 and TOPAZ-2 lupus trials in December
    Biogen is set to release the readout from two pivotal Phase 3 studies, TOPAZ-1 and TOPAZ-2, evaluating its lupus drug litifilimab. The data are expected in the first half of December and will be th…
    STAT · 5d agoPositive readoutNeutral↗ source
  • Study finds Black Americans share many concerns with MAHA despite low overall support
    Jerel Ezell, an epidemiologist at the University of Chicago Medical Center, writes an opinion piece examining the complex relationship between the MAHA movement and Black Americans. A 2025 poll by…
    STAT · 5d agoNeutral↗ source